CoChat

A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors

Open access
Ahmad, Syed, Hughes, Mark A, Lane, Kimberly T, Redinbo, Matthew R, Yeh, Li-An, Scott, John E · 2011 · Current Chemical Genomics

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

CPT-11 is a widely-used anti-cancer drug that is converted in vivo to its active metabolite, SN-38. In the liver, enzymes detoxify SN-38 by coupling it to a glucuronidate moiety and this inactive compound (SN-38G) is excreted into the gastrointestinal tract. In the intestine, commensal bacteria convert the SN-38G back to the active and toxic SN-38 using bacterial β-glucuronidase enzyme (GUS). This intestinal SN-38 causes debilitating diarrhea that prevents dose-intensification and efficacy in a significant fraction of patients undergoing CPT-11 treatment for cancer. This CPT-11 metabolic pathway suggests that small molecule inhibitors of GUS may have utility as novel therapeutics for prevention of dose-limiting diarrhea resulting from CPT-11 therapy. To identify chemical inhibitors of GUS activity, we employed and validated a high throughput, fluorescence-based biochemical assay and used this assay to screen a compound library. Novel inhibitors of GUS were identified with IC(50) values ranging from 50 nM to 4.8 µM. These compounds may be useful as chemical probes for use in proof-of-concept experiments designed to determine the efficacy of GUS inhibitors in altering the intestinal metabolism of drugs. Our results demonstrate that this high throughput assay can be used to identify small molecule inhibitors of GUS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1875397301105010013

Cites

Statistics

Figures

Fig. (1) Schematic of the GUS high throughput enzyme assay.
Fig. (1) Schematic of the GUS high throughput enzyme assay.CC BY-NC · PubMed Central
Fig. (2) GUS enzyme titration. GUS was titrated into the assay under final assay conditions with an incubation time of 30 min in the presence of 1% DMSO. Data points represent the average of three determinations per concentration and error bars represent standard deviations. Data are representative of three independent experiments.
Fig. (2) GUS enzyme titration. GUS was titrated into the assay under final assay conditions with an incubation time of 30 min in the presence of 1% DMSO. Data points represent the average of three determinations per concentration and error bars represent standard deviations. Data are representative of three independent experiments.CC BY-NC · PubMed Central
Fig. (3) GUS assay time course. A time course study was performed under final assay conditions in the presence of 1% DMSO. Data points represent the average of three determinations per time point and error bars represent standard deviations. Data are representative of three independent experiments.
Fig. (3) GUS assay time course. A time course study was performed under final assay conditions in the presence of 1% DMSO. Data points represent the average of three determinations per time point and error bars represent standard deviations. Data are representative of three independent experiments.CC BY-NC · PubMed Central
Fig. (4) DMSO tolerance of GUS assay. The indicated concentrations of DMSO were tested in the GUS assay. Data points represent the average of three determinations per concentration and error bars represent standard deviations. Data are representative of three independent experiments.
Fig. (4) DMSO tolerance of GUS assay. The indicated concentrations of DMSO were tested in the GUS assay. Data points represent the average of three determinations per concentration and error bars represent standard deviations. Data are representative of three independent experiments.CC BY-NC · PubMed Central
Fig. (5) GUS assay variability assessment. All wells of a 384-well plate were pre-spotted with 0.5 µl of DMSO. Two plates each were used to determine the maximum signal (■) and minimum signal (●).
Fig. (5) GUS assay variability assessment. All wells of a 384-well plate were pre-spotted with 0.5 µl of DMSO. Two plates each were used to determine the maximum signal (■) and minimum signal (●).CC BY-NC · PubMed Central
Fig. (6) IC50 value determinations using the automated GUS assay. Data points represent the average of three determinations per concentration and error bars represent standard deviations. Data are representative of two independent experiments.
Fig. (6) IC50 value determinations using the automated GUS assay. Data points represent the average of three determinations per concentration and error bars represent standard deviations. Data are representative of two independent experiments.CC BY-NC · PubMed Central
Fig. (7) Screen of the Prestwick collection with the GUS assay. Each point represents a compound. The percent inhibition values were calculated relative to controls on the plates.
Fig. (7) Screen of the Prestwick collection with the GUS assay. Each point represents a compound. The percent inhibition values were calculated relative to controls on the plates.CC BY-NC · PubMed Central
Fig. (8) IC50 value determination for two screen hits. Compounds were serially diluted in 100% DMSO then transferred to assay plates for the GUS activity assay. Concentration response curves are shown for two representative hits from the screen.
Fig. (8) IC50 value determination for two screen hits. Compounds were serially diluted in 100% DMSO then transferred to assay plates for the GUS activity assay. Concentration response curves are shown for two representative hits from the screen.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 35 · Cited by 29

Research works printed but not linked: 1

  1. [4]Pizzolato JF Saltz LB The camptothecins Lancet 2003 361 9376 2235 42 12842380

Metadata

Authors
Ahmad, S., Hughes, M. A., Lane, K. T., Redinbo, M. R., Yeh, L.-A., & Scott, J. E.
Affiliations
  • North Carolina Central University (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Scott, John E
Venue
Current Chemical Genomics
Published
2011-04-08
Volume
5
Pages
13-20
ISSN
1875-3973 (ISSN-L)
OpenAlex
W2046850261
Cited by
29
References
35
Citations by year
2026: 4 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 2 · 2018: 2 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 1 · 2012: 2
FWCI
1.35
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Current Chemical Genomics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Golden LEAF Foundation
  • National Institutes of Health
  • National Cancer Institute (R01CA098468)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
β-glucuronidase inhibitors, SN-38, irinotecan, drug metabolism, intestinal drug metabolism, small molecule inhibitors, gut commensal bacteria, chemical probes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors. https://app.cochat.ai/papers/10.2174/1875397301105010013
The paper
Ahmad, S., Hughes, M. A., Lane, K. T., Redinbo, M. R., Yeh, L.-A., & Scott, J. E. (2011). A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors. Current Chemical Genomics. https://doi.org/10.2174/1875397301105010013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.